Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53 peptide vaccine in metastatic colorectal cancer after treatment of liver metastases
NL-OMON24376Phase 2Recruiting
- Sponsor
- N/A
- Start
- Nov 2006
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of p53 synthetic long peptide vaccine and montanide isa-51 in colorectal cancer (CRC), sponsored by N/A. Primary endpoints: Safety and Immunogenicity. Started Nov 2006; status: recruiting.
02
Drugs
p53 synthetic long peptide vaccinemontanide isa-51
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON24376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24376.